Cargando…

Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia

Optimized strategies for risk classification are essential to tailor therapy for patients with biologically distinctive disease. Risk classification in pediatric acute myeloid leukemia (pAML) relies on detection of translocations and gene mutations. Long noncoding RNA (lncRNA) transcripts have been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farrar, Jason E., Smith, Jenny L., Othus, Megan, Huang, Benjamin J., Wang, Yi-Cheng, Ries, Rhonda, Hylkema, Tiffany, Pogosova-Agadjanyan, Era L., Challa, Sneha, Leonti, Amanda, Shaw, Timothy I., Triche, Timothy J., Gamis, Alan S., Aplenc, Richard, Kolb, E. Anders, Ma, Xiaotu, Stirewalt, Derek L., Alonzo, Todd A., Meshinchi, Soheil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2023
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414715/ https://www.ncbi.nlm.nih.gov/pubmed/36795987 http://dx.doi.org/10.1200/JCO.22.01114

Ejemplares similares

A B-cell developmental gene regulatory network is activated in infant AML
por: Bolouri, Hamid, et al.
Publicado: (2021)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes
por: Huang, Benjamin J., et al.
Publicado: (2021)

Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML
por: Stirewalt, D L, et al.
Publicado: (2014)

Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia
por: Bertrums, Eline J. M., et al.
Publicado: (2023)

Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia
por: Huang, Benjamin J., et al.
Publicado: (2022)

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network
por: Termini, Christina M., et al.
Publicado: (2023)

Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients
por: Pogosova-Agadjanyan, Era L., et al.
Publicado: (2023)

The Prognostic Significance of IRF8 Transcripts in Adult Patients with Acute Myeloid Leukemia
por: Pogosova-Agadjanyan, Era L., et al.
Publicado: (2013)

Gene Expression Patterns in Myelodyplasia Underline the Role of Apoptosis and Differentiation in Disease Initiation and Progression
por: Bar, Merav, et al.
Publicado: (2008)

SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia
por: Marrero, Richard J., et al.
Publicado: (2023)

AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report
por: Pogosova-Agadjanyan, Era L., et al.
Publicado: (2020)

Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group
por: Nagarajan, Rajaram, et al.
Publicado: (2019)

MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia
por: Lim, Emilia L., et al.
Publicado: (2017)

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study
por: Halpern, Anna B., et al.
Publicado: (2017)

Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes
por: Bolouri, Hamid, et al.
Publicado: (2022)

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group
por: Aplenc, Richard, et al.
Publicado: (2020)

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study
por: Hoff, Fieke W., et al.
Publicado: (2022)

Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group
por: Vujkovic, Marijana, et al.
Publicado: (2016)

Transcriptome Profiling of Pediatric Core Binding Factor AML
por: Hsu, Chih-Hao, et al.
Publicado: (2015)

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2015)

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2016)

ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial
por: Rafiee, Roya, et al.
Publicado: (2019)

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
por: Le, Quy, et al.
Publicado: (2021)

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
por: McNeer, Nicole A., et al.
Publicado: (2019)

Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival
por: Pommert, Lauren, et al.
Publicado: (2022)

MicroRNA-150 Expression Induces Myeloid Differentiation of Human Acute Leukemia Cells and Normal Hematopoietic Progenitors
por: Morris, Valerie A., et al.
Publicado: (2013)

Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia
por: Narayanan, P., et al.
Publicado: (2021)

Ethnic Variation of TET2 SNP rs2454206 and Association with Clinical Outcome in Childhood AML: A Report from the Children’s Oncology Group
por: Kutny, Matthew A., et al.
Publicado: (2015)

Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia
por: Le, Quy, et al.
Publicado: (2023)

Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study
por: Ho, Phoenix A., et al.
Publicado: (2010)

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531
por: Voigt, Andrew P., et al.
Publicado: (2017)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target
por: Le, Quy, et al.
Publicado: (2022)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
por: Lamba, Jatinder K., et al.
Publicado: (2021)

Early discharge as a mediator of greater ICU‐level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report
por: Getz, Kelly D., et al.
Publicado: (2016)

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
por: Laszlo, George S., et al.
Publicado: (2016)

bamSliceR: cross-cohort variant and allelic bias analysis for rare variants and rare diseases
por: Huang, Yizhou Peter, et al.
Publicado: (2023)

Merging Children’s Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children’s Oncology Group
por: Li, Yimei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_81frv54oclk0qib79aitiqlaap